doc.ai Digital Health Trial Aims to Improve Precision in Epilepsy Treatment

The study, led by principal investigator Robert Fisher, MD PhD, professor of neurology and neurological sciences at the Stanford University School of Medicine and director of the Stanford Epilepsy Center, will deploy and test A.I. to develop a predictive model for treatment. Epilepsy, a neurological disorder characterized by unprovoked and recurrent seizures, affects 65 million people across the globe and 3.4 million in the United States. While the cause of seizures is largely unknown, more than 25 medications have been developed to help manage symptoms. The method of drug delivery is still largely a matter of trial and error with over 14,000 possible combinations of up to three drugs to analyze and correlate for treatment, leaving patients suffering from severe side effects and adverse reactions, sometimes for years. "We're testing our A.I. capabilities to help clinicians and their patients to find the optimal anti-seizure drug for an individual," said Walter De Brouwer, CEO of doc.ai.